Dr Jaimini Cegla
Disclosure details
Jaimini Cegla has received lecture honoraria, consultancy fees, and/or research funding from Novartis, Amgen, Sobi, Amryt, Pfizer, Daiichi Sankyo, Sanofi, Ultragenyx, Verve Therapeutics and Silence Therapeutics.Clinical Lead for the Lipids and Cardiovascular Risk Service, Consultant in Chemical Pathology and Metabolic Medicine, Imperial College Healthcare NHS Trust; Senior Clinical Lecturer, Department of Diabetes, Endocrinology and Metabolism, Imperial College London, UK
